Cholesterol Absorption Inhibitors Class Overview Monograph

Mechanism of Action and Pharmacology

Ezetimibe targets the NPC1L1 protein expressed on the luminal surface of jejunal enterocytes. NPC1L1 is the principal sterol transporter mediating intestinal absorption of dietary and biliary cholesterol. By selectively binding this transporter, ezetimibe reduces cholesterol delivery to hepatocytes, upregulating hepatic LDL receptor expression and increasing LDL-C clearance from plasma 1.

Molecular Pharmacology of NPC1L1

NPC1L1 contains a sterol-sensing domain structurally related to HMG-CoA reductase and SCAP. Genetic studies of NPC1L1 loss-of-function variants in over 113,000 individuals showed a 53% lower risk of coronary heart disease, providing Mendelian randomization support for ezetimibe's target 2. NPC1L1 is also expressed on the canalicular membrane of hepatocytes, where it recaptures biliary cholesterol. Ezetimibe's glucuronide metabolite inhibits both intestinal and hepatic NPC1L1, contributing to its efficacy through enterohepatic recirculation 3.

Pharmacokinetics

After oral administration, ezetimibe is rapidly absorbed and conjugated to ezetimibe-glucuronide, its pharmacologically active metabolite. Peak plasma concentrations occur within 1 to 2 hours for the parent compound and 4 to 12 hours for the glucuronide 4. Enterohepatic recycling gives an effective half-life of approximately 22 hours, supporting once-daily dosing. Ezetimibe does not inhibit cytochrome P450 enzymes, which accounts for its low drug interaction profile. Hepatic impairment (Child-Pugh B or C) increases exposure and is a relative contraindication per the FDA label 5.

Compensatory Cholesterol Synthesis

Blocking intestinal absorption triggers a compensatory increase in hepatic cholesterol synthesis, typically 30 to 40%. This reflex partially offsets ezetimibe monotherapy efficacy. Combining ezetimibe with a statin suppresses both absorption and synthesis pathways simultaneously, producing complementary LDL-C lowering that exceeds either mechanism alone 6.

Efficacy: Key Clinical Trials

The clinical evidence base for ezetimibe spans LDL-C lowering studies, cardiovascular outcome trials, and renal outcome data. Three trials define the class.

IMPROVE-IT (N=18,144)

IMPROVE-IT randomized 18,144 patients with acute coronary syndrome to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At a median follow-up of 6 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-only arm. The primary composite endpoint (cardiovascular death, major coronary event, or stroke) occurred in 32.7% of the combination group versus 34.7% of the monotherapy group (HR 0.936, 95% CI 0.89 to 0.99, P=0.016) 7. IMPROVE-IT was the first trial to show that a non-statin LDL-C-lowering agent reduces cardiovascular events when added to statin therapy.

The absolute risk reduction of 2.0 percentage points translated to a number needed to treat of 50 over 7 years. Diabetic patients (N=4,933) derived larger absolute benefit, with a 5.5 percentage-point reduction in the primary endpoint 8.

SHARP (N=9,270)

The Study of Heart and Renal Protection randomized 9,270 patients with chronic kidney disease (CKD) to simvastatin 20 mg plus ezetimibe 10 mg versus placebo. At 4.9 years of median follow-up, the combination reduced major atherosclerotic events by 17% (RR 0.83, 95% CI 0.74 to 0.94, P=0.0021). LDL-C fell by 0.85 mmol/L (33 mg/dL) in the treatment arm. No excess in cancer, myopathy, hepatotoxicity, or rhabdomyolysis was detected 9. SHARP remains the largest lipid-lowering trial in CKD and directly informed the 2013 KDIGO guideline recommendation for statin-ezetimibe in CKD patients 10.

SEAS (N=1,873)

The Simvastatin and Ezetimibe in Aortic Stenosis trial tested whether LDL-C lowering would slow aortic valve disease progression. Over 52.2 months, simvastatin-ezetimibe did not reduce the combined primary endpoint of aortic valve events and ischemic cardiovascular events (HR 0.96, P=0.59). The ischemic cardiovascular event component alone was reduced by 22% (P=0.02), but the valve disease component showed no benefit 11. SEAS clarified that cholesterol lowering does not modify established calcific aortic stenosis, a finding consistent with statin trial data in this population.

Guideline Positioning

The 2018 ACC/AHA Cholesterol Guideline positions ezetimibe as first-line add-on therapy when maximally tolerated statin does not achieve adequate LDL-C reduction. For patients with clinical ASCVD and LDL-C ≥70 mg/dL on maximally tolerated statin, the guideline recommends adding ezetimibe before considering a PCSK9 inhibitor 12.

Role in Statin Intolerance

For patients who cannot tolerate any statin dose, ezetimibe monotherapy provides a 15 to 22% LDL-C reduction with a safety profile comparable to placebo in randomized trials. The 2022 EAS Consensus Statement on statin-associated muscle symptoms recommends ezetimibe as an alternative first-line agent when two statin rechallenge attempts have failed 13.

Combination With PCSK9 Inhibitors

Triple therapy (statin plus ezetimibe plus a PCSK9 inhibitor) can achieve LDL-C levels below 25 mg/dL. In a prespecified FOURIER subanalysis, patients on background ezetimibe who received evolocumab achieved a median LDL-C of 19 mg/dL versus 33 mg/dL without background ezetimibe 14. Current ACC/AHA guidance reserves PCSK9 inhibitors for patients whose LDL-C remains above threshold after statin plus ezetimibe.

Pediatric Guideline Use

The 2011 National Heart, Lung, and Blood Institute expert panel guidelines recommend ezetimibe as second-line therapy in children aged 10 years and older with familial hypercholesterolemia when statin monotherapy is insufficient 15.

Prescribing and Dosing

Ezetimibe prescribing is straightforward. The dose is 10 mg once daily for all approved indications, with no titration.

Indications

FDA-approved indications include primary hyperlipidemia (as monotherapy or combined with a statin), homozygous familial hypercholesterolemia (combined with a statin or with atorvastatin and fenofibrate), homozygous sitosterolemia, and mixed hyperlipidemia (combined with fenofibrate) 5. Off-label use with bempedoic acid is increasingly common, and the fixed-dose combination of bempedoic acid 180 mg plus ezetimibe 10 mg (Nexlizet) was FDA-approved in 2020 16.

Administration Considerations

Ezetimibe can be taken with or without food. It can be dosed at any time of day. When combined with a statin, both drugs may be taken together. Bile acid sequestrants reduce ezetimibe absorption; if co-prescribed, ezetimibe should be administered ≥2 hours before or ≥4 hours after the sequestrant 5.

Fixed-Dose Combinations

Two fixed-dose combination products are commercially available. Vytorin (ezetimibe 10 mg/simvastatin 10, 20, 40, or 80 mg) and Nexlizet (bempedoic acid 180 mg/ezetimibe 10 mg). Generic ezetimibe-simvastatin is available, reducing cost barriers for dual therapy.

Safety and Tolerability

Ezetimibe's adverse event profile is consistently near-placebo across large randomized trials. This low-risk profile makes it one of the most tolerable lipid-lowering agents available.

Common Adverse Effects

In pooled phase III data (N=2,396 ezetimibe-treated, N=1,159 placebo), the most frequently reported events were upper respiratory tract infection (4.3% vs. 2.5%), diarrhea (4.1% vs. 3.7%), arthralgia (3.0% vs. 2.2%), sinusitis (2.8% vs. 2.2%), and extremity pain (2.7% vs. 2.5%) 5. No dose-dependent adverse event signal exists because only one dose (10 mg) is marketed.

Hepatotoxicity Monitoring

When ezetimibe is combined with a statin, the hepatotoxicity risk is driven by the statin component. In IMPROVE-IT, consecutive ALT elevations >3× ULN occurred in 2.5% of the ezetimibe-simvastatin group versus 2.3% of the simvastatin-only group, a non-significant difference 7. The FDA label does not mandate routine liver enzyme monitoring for ezetimibe monotherapy but recommends testing at baseline when co-prescribed with a statin.

Myopathy and Rhabdomyolysis

Ezetimibe monotherapy does not cause statin-type myopathy. In IMPROVE-IT, myopathy rates were 0.2% in both arms. Rhabdomyolysis occurred in <0.1% of patients regardless of treatment assignment 7. Ezetimibe may be co-prescribed with lower statin doses to reduce myalgia burden while maintaining LDL-C target attainment.

Cancer Signal: Resolved

An early pooled analysis of SEAS and IMPROVE-IT raised concern about increased cancer incidence with ezetimibe. The completed IMPROVE-IT trial, with 18,144 patients followed for a median of 6 years, showed no difference in total cancer incidence (9.4% vs. 9.5%) or cancer mortality, definitively resolving this safety signal 7.

Drug Interactions

Ezetimibe has a narrow drug interaction profile because it does not use CYP450 metabolism for its primary clearance pathway.

Clinically Relevant Interactions

Cyclosporine increases ezetimibe AUC by approximately 3.4-fold. The FDA label recommends caution and monitoring of cyclosporine levels in transplant patients taking ezetimibe 5. Fibrates (except fenofibrate) may increase gallstone risk when combined with ezetimibe, and gemfibrozil specifically increases ezetimibe exposure by 1.7-fold. The combination of ezetimibe with gemfibrozil is not recommended.

Warfarin

Ezetimibe does not alter warfarin pharmacokinetics or INR in dedicated interaction studies. No dose adjustment is needed 5.

Statin Interactions

Ezetimibe does not alter statin plasma concentrations in clinically meaningful ways. No dose adjustment of any co-administered statin is required when adding ezetimibe 4.

Special Populations

Chronic Kidney Disease

SHARP established benefit in CKD stages 3 to 5 including dialysis patients. No dose adjustment is required in renal impairment 9. KDIGO 2013 guidelines specifically recommend statin-ezetimibe combination for adults aged ≥50 years with eGFR <60 mL/min/1.73 m² not on dialysis 10.

Hepatic Impairment

Ezetimibe exposure increases in moderate to severe hepatic impairment (Child-Pugh B and C). The drug is not recommended in active liver disease or unexplained persistent transaminase elevations when combined with a statin 5.

Pregnancy and Lactation

Ezetimibe is classified as Category C. Animal studies showed no teratogenicity at exposures up to 10 times the human dose, but no adequate human data exist. When combined with a statin, the combination is contraindicated in pregnancy because of the statin component. Excretion in human breast milk is unknown 5.

Geriatric Patients

No dose adjustment is necessary in elderly patients. In IMPROVE-IT, patients aged ≥75 years (N=2,798) derived similar relative cardiovascular benefit as younger patients, with a greater absolute risk reduction given their higher baseline event rate 17.

Emerging Combination Strategies

Bempedoic Acid Plus Ezetimibe

The CLEAR Outcomes trial (N=13,970) demonstrated that bempedoic acid reduced major adverse cardiovascular events by 13% in statin-intolerant patients. Approximately 17% of CLEAR participants also took ezetimibe at baseline 18. The fixed-dose Nexlizet combination provides a statin-free LDL-C reduction of approximately 38%, making it the most potent oral non-statin regimen available.

Inclisiran Sequencing

For patients on maximally tolerated statin plus ezetimibe who remain above LDL-C threshold, inclisiran (a small interfering RNA targeting PCSK9 hepatic synthesis) offers twice-yearly dosing. The ORION-10 trial (N=1,561) showed 52% LDL-C reduction with inclisiran on top of background therapy that included ezetimibe in 8% of participants 19. ACC/AHA guidance does not yet specify the preferred order of PCSK9 monoclonal antibody versus inclisiran after ezetimibe add-on failure.

The Endocrine Society and ADA 2024 Standards of Care both affirm ezetimibe as second-line add-on for patients with diabetes and elevated ASCVD risk 20.